Reduction in infection-related mortality since modifications in the regimen of medical abortion

被引:13
作者
Trussell, James [1 ,2 ]
Nucatola, Deborah [3 ]
Fjerstad, Mary [4 ]
Lichtenberg, E. Steve [5 ]
机构
[1] Princeton Univ, Off Populat Res, Princeton, NJ 08544 USA
[2] Univ Hull, Hull York Med Sch, Kingston Upon Hull HU6 1RX, N Humberside, England
[3] Planned Parenthood Federat Amer, New York, NY 10001 USA
[4] WomanCare Global, San Diego, CA 92122 USA
[5] Northwestern Univ, Feinberg Sch Med, Chicago, IL 60611 USA
关键词
Medical abortion; Mortality; Doxycycline; Buccal misopristol; Clostridia; UNITED-STATES; MIFEPRISTONE; MISOPROSTOL;
D O I
10.1016/j.contraception.2013.11.020
中图分类号
R71 [妇产科学];
学科分类号
100211 ;
摘要
Background: From 2001 to March 2006 Planned Parenthood health centers throughout the United States provided medical abortion by a regimen of oral mifepristone followed 24-48 h later by vaginal misoprostol. In response to concerns about serious infections, in early 2006 Planned Parenthood changed the route of misoprostol administration to buccal and required either routine antibiotic coverage or universal screening and treatment for chlamydia; in July 2007, Planned Parenthood began requiring routine antibiotic coverage for all medical abortions. Methods: We performed a retrospective analysis of Planned Parenthood cases assessing the rates of mortality caused by infection following medical abortion during a time period when misoprostol was administered vaginally (2001 through March 2006), as compared with the rate from April 2006 to the end of 2012 after a change to buccal administration of misoprostol and after initiation of new infection-reduction strategies. Results: The mortality rate dropped significantly in the 81-month period after the joint change to (1) buccal misoprostol replacing vaginal misoprostol and (2) either sexually transmitted infection (STI) screening or routine preventative antibiotic coverage (15 month period) or universal routine preventative antibiotic coverage as part of the medical abortion (66-month period), from 1.37/100,000 to 0.00/100,000, P=.013 (difference=1.37/100,000, 95% CI 0.47-4.03 per 100,000). Conclusion: The infection-caused mortality rate following medical abortion declined by 100% following a change from vaginal to buccal administration of misoprostol combined with screen-and-treat or, far more commonly, routine antibiotic coverage. Significance: Deaths from infection following medical abortion declined to zero after a change in the regimen. (C) 2014 Elsevier Inc. All rights reserved.
引用
收藏
页码:193 / 196
页数:4
相关论文
共 13 条
[1]  
[Anonymous], GON IS SURV PROJ GIS
[2]   Pregnancy-Related Mortality in the United States, 1998 to 2005 [J].
Berg, Cynthia J. ;
Callaghan, William M. ;
Syverson, Carla ;
Henderson, Zsakeba .
OBSTETRICS AND GYNECOLOGY, 2010, 116 (06) :1302-1309
[3]  
Cleland K, 2013, OBSTET GYNECOL, V121, P166, DOI [10.1097/AOG.0b013e3182755763, http://10.1097/AOG.0b013e3182755763]
[4]   Deaths associated with medication abortion [J].
Darney, PD .
CONTRACEPTION, 2005, 72 (04) :319-319
[5]   Brief report -: Fatal toxic shock syndrome associated with Clostridium sordellii after medical abortion [J].
Fischer, M ;
Bhatnagar, J ;
Guarner, J ;
Reagan, S ;
Hacker, JK ;
Van Meter, SH ;
Poukens, V ;
Whiteman, DB ;
Iton, A ;
Cheung, M ;
Dassey, DE ;
Shieh, WJ ;
Zaki, SR .
NEW ENGLAND JOURNAL OF MEDICINE, 2005, 353 (22) :2352-2360
[6]   Effectiveness of medical abortion with mifepristone and buccal misoprostol through 59 gestational days [J].
Fjerstad, Mary ;
Sivin, Irving ;
Lichtenberg, E. Steve ;
Trussell, James ;
Cleland, Kelly ;
Cullins, Vanessa .
CONTRACEPTION, 2009, 80 (03) :282-286
[7]   Rates of Serious Infection after Changes in Regimens for Medical Abortion. [J].
Fjerstad, Mary ;
Trussell, James ;
Sivin, Irving ;
Lichtenberg, E. Steve ;
Cullins, Vanessa .
NEW ENGLAND JOURNAL OF MEDICINE, 2009, 361 (02) :145-151
[8]   Mifepristone and misoprostol for early medical abortion: 18 months experience in the United States [J].
Hausknecht, R .
CONTRACEPTION, 2003, 67 (06) :463-465
[9]   Safety of mifepristone abortions in clinical use [J].
Henderson, JT ;
Hwang, AC ;
Harper, CC ;
Stewart, FH .
CONTRACEPTION, 2005, 72 (03) :175-+
[10]  
Sawaya GF, 1996, OBSTET GYNECOL, V87, P884